PRME News & Events

Latest data shows the largest indicative borrow rate increases among liquid option names include: LASER PHOTONICS CORPORATION (LASE) 88.51% +3.92, EETH ETF (EETH) 18.17% +0.92, iShares MSCI Europe (EUFN) 4.40% +0.83, Tidal Trust II (IRE) 38.76% +0.79, Palladyne AI Corp (PDYN) 21.74% +0.53, Beyond Meat (BYND) 29.78% +0.44, ChargePoint Holdings (CHPT) 10.57% +0.39, Velo3D Inc (VELO) 8.09% +0.39, Prime Medicine Inc (PRME) 0.99% +0.37, and Energy Transfer (ET) 3.90% +0.36.

Reports FY25 $4.632M vs $2.983M last year. "We are shaping the future of genetic medicine by advancing a platform that is rapidly emerging as the predominant gene editing technology. With Prime Editing, we have the opportunity to permanently and safely correct disease-causing mutations across a broad range of indications, supported by our comprehensive IP estate," said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. "With this foundation, our vision is bold and unwavering: to strategically deliver on the promise of Prime Editing and ensure patients have access to transformative therapies capable of delivering durable, and potentially lasting cures. This begins with PM359, our ex vivo Prime Edited autologous HSC product for CGD, for which we announced breakthrough data in 2025, which we believe supports an accelerated approval in the United States."

Prime Medicine announced the publication of Phase 1/2 clinical data with PM359, the Company's investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease, CGD, in the New England Journal of Medicine, NEJM. The data will also be presented in a poster session at the 67th American Society of Hematology, ASH, Annual Meeting, December 6-9, 2025 in Orlando, Florida. The publication, titled "Prime Editing for p47-phox Chronic Granulomatous Disease," reports initial data for two patients treated in the Phase 1/2 trial of PM359, which was designed to assess safety, biological activity and preliminary efficacy in adult and pediatric study participants. Results: Both patients enrolled in the study had a history of prior CGD-defining complications; Both patients experienced rapid neutrophil engraftment, achieving 69% and 83% dihydrorhodamine-positive neutrophils by Day 30; Both patients remain free of new CGD-related complications or significant intercurrent illnesses post-infusion; No clinically significant adverse events attributable to PM359 occurred in either patient, and all observed toxicities were consistent with busulfan-based conditioning.